AIM: To determine the frequency of tumour budding and somatic APC mutation in a series of colorectal cancers stratified according to DNA microsatellite instability (MSI) status. MATERIAL/ METHODS: Ninety five colorectal cancers were genotyped for APC mutation in the mutation cluster region (exon 15) and scored for the presence of tumour budding at the invasive margin in haematoxylin and eosin stained sections. A subset was immunostained for beta catenin and p16. RESULTS: The frequency of both somatic APC mutation and tumour budding increased pari passu in cancers stratified as sporadic MSI high (MSI-H), hereditary non-polyposis colorectal cancer (HNPCC), MSI low (MSI-L), and microsatellite stable (MSS). Both budding and APC mutation were significantly less frequent in sporadic MSI-H cancers than in MSI-L or MSS cancers. Tumour buds were characterised by increased immunostaining for both beta catenin and p16. CONCLUSION: Tumour budding is associated with an adverse prognosis. The lack of budding in MSI-H colorectal cancer may account for the improved prognosis of this subset and may be explained by an intact WNT signalling pathway and/or inactivated p16(INK4a).
AIM: To determine the frequency of tumour budding and somatic APC mutation in a series of colorectal cancers stratified according to DNA microsatellite instability (MSI) status. MATERIAL/ METHODS: Ninety five colorectal cancers were genotyped for APC mutation in the mutation cluster region (exon 15) and scored for the presence of tumour budding at the invasive margin in haematoxylin and eosin stained sections. A subset was immunostained for beta catenin and p16. RESULTS: The frequency of both somatic APC mutation and tumour budding increased pari passu in cancers stratified as sporadic MSI high (MSI-H), hereditary non-polyposis colorectal cancer (HNPCC), MSI low (MSI-L), and microsatellite stable (MSS). Both budding and APC mutation were significantly less frequent in sporadic MSI-H cancers than in MSI-L or MSS cancers. Tumour buds were characterised by increased immunostaining for both beta catenin and p16. CONCLUSION:Tumour budding is associated with an adverse prognosis. The lack of budding in MSI-H colorectal cancer may account for the improved prognosis of this subset and may be explained by an intact WNT signalling pathway and/or inactivated p16(INK4a).
Authors: M Esteller; R A Risques; M Toyota; G Capella; V Moreno; M A Peinado; S B Baylin; J G Herman Journal: Cancer Res Date: 2001-06-15 Impact factor: 12.701
Authors: E Kapiteijn; G J Liefers; L C Los; E K Kranenbarg; J Hermans; R A Tollenaar; Y Moriya; C J van de Velde; J H van Krieken Journal: J Pathol Date: 2001-09 Impact factor: 7.996
Authors: A Jung; M Schrauder; U Oswald; C Knoll; P Sellberg; R Palmqvist; G Niedobitek; T Brabletz; T Kirchner Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307
Authors: J R Jass; K G Biden; M C Cummings; L A Simms; M Walsh; E Schoch; S J Meltzer; C Wright; J Searle; J Young; B A Leggett Journal: J Clin Pathol Date: 1999-06 Impact factor: 3.411
Authors: M Esteller; M Toyota; M Sanchez-Cespedes; G Capella; M A Peinado; D N Watkins; J P Issa; D Sidransky; S B Baylin; J G Herman Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: Tamara L Znajda; Shinichi Hayashi; Peter J Horton; John B Martinie; Prosanto Chaudhury; Victoria A Marcus; Jeremy R Jass; Peter Metrakos Journal: J Gastrointest Surg Date: 2006-04 Impact factor: 3.452
Authors: Irene Centeno; Aino Paasinen Sohns; Miriam Flury; José A Galván; Stefan Zahnd; Viktor H Koelzer; Lena Sokol; Heather E Dawson; Alessandro Lugli; Gieri Cathomas; Inti Zlobec Journal: Virchows Arch Date: 2017-01-27 Impact factor: 4.064
Authors: Zhengyu Fang; Yi Xiong; Jiana Li; Li Liu; Manhui Li; Wei Zhang; Lei Shi; Jun Wan Journal: Pathol Oncol Res Date: 2011-02-26 Impact factor: 3.201
Authors: Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal Journal: Nat Rev Clin Oncol Date: 2020-09-08 Impact factor: 66.675
Authors: R Fukuyama; R Niculaita; K P Ng; E Obusez; J Sanchez; M Kalady; P P Aung; G Casey; N Sizemore Journal: Oncogene Date: 2008-06-30 Impact factor: 9.867